The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) consortium is pleased to announce the release of updated raw and harmonised datasets from the AMYPAD Prognostic and Natural History Study (PNHS). The new data are now available through the Alzheimer’s Disease Data Initiative (AD Data Initiative) AD Workbench.

The updated release includes participants’ demographic data, clinical outcomes such as cognitive assessments, disease biomarkers (imaging and CSF), risk factors (e.g., genetics and environmental), and other relevant variables. New additions to this release include computed polygenic risk scores from harmonised genotype array data, a comprehensive set of imaging-derived endophenotypes from various MRI processing pipelines and corrections to selected cognition-related scores.

Information about the AMYPAD Prognostic and Natural History Study

The AMYPAD Prognostic and Natural History Study (PNHS) is an open-label, prospective, multicentre, cohort study linked to a variety of European Parent Cohorts.

AMYPAD PNHS aims to improve disease modelling efforts and individualized risk stratification within the context of Alzheimer’s disease through the additional collection of amyloid burden using positron emission tomography (PET) imaging.

Information about the raw AMYPAD PNHS dataset

The raw AMYPAD PNHS dataset integrates information from 9 Parent Cohorts: ALFA+, AMYPAD DPMS, EMIF-AD (60++), EMIF-AD (90+), EPAD LCS, FACEHBI, FPACK, Microbiota, and UCL-2010-412, comprising a total of 3266 participants. Of these, 1518 underwent a baseline amyloid PET, including visual reads and the Centiloid quantification (1454 subjects) among other metrics. Moreover, 855 participants have (at least) one follow-up PET scan, 851 of whom have Centiloid quantification.

Information about the harmonised AMYPAD PNHS dataset

The harmonised AMYPAD PNHS dataset integrates information from 10 Parent Cohorts: ALFA+, AMYPAD DPMS, DELCODE, EMIF-AD (60++), EMIF-AD (90+), EPAD LCS, FACEHBI, FPACK, Microbiota, and UCL-2010-412, comprising a total of 3368 participants. Of these, 1620 underwent a baseline amyloid PET, including visual reads and the Centiloid quantification (1476 subjects) among other metrics. Moreover, 888 participants have (at least) one follow-up PET scan, 884 of whom have Centiloid quantification.

Data access

AMYPAD offers a way of accessing the data to academic researchers, institutions and companies from all over the world. This is shared through secure online Workspaces and you will need to make a formal request to access the imaging, clinical, and biomarker data for scientific research investigation and/or educational activities. The application can be performed via the FAIR Data Service of the Alzheimer’s Disease Data Initiative (https://fair.addi.ad-datainitiative.org/#/data/home).

Useful links

• Contributors list:  5281/zenodo.21032677
• Data access request:  5281/zenodo.21032898
• Data use agreement:  5281/zenodo.21032957
• Publication policy:  5281/zenodo.21032996
• List of variables: 5281/zenodo.21035560
• AMYPAD PNHS – Integrated dataset (Raw) v202606: 5281/zenodo.18622442
• AMYPAD PNHS – Integrated dataset (Harmonized and Derived) v202606: 5281/zenodo.18622389